Astria Therapeutics Inc

Astria Therapeutics — Catabasis Pharmaceuticals — Investor Presentation (December 2017)

35 slides from Astria Therapeutics's investor presentation, Dec 11, 2017

  1. Slide 1: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding our expectations and beliefs about our business, future financial and operating performance, clinical trial plan

  2. Slide 2: Advancing Rare Disease Pipeline

    Advancing Rare Disease Pipeline Edasalonexent: Preparing for Phase 3 trial in Duchenne muscular dystrophy (DMD) An oral inhibitor of NF-B for all DMD patients regardless of mutation type In the MoveDMD® trial, edasalonexent substantially slowed DMD disease progression and functional decline with cli

  3. Slide 3: Pipeline of Product Candidates in Rare Diseases

    Pipeline of Product Candidates in Rare Diseases e ase 3 in uscular dystrophy are disease • s ataxia • Con All product candidates have been developed using our proprietary SMART LinkerSM Drug Discovery platform 4 Product Candidate (Pathway) Discovery Preclin Phase 1 Phase 2 Phase 3 Edasalonexent CAT-

  4. Slide 4: Edasalonexent (CAT-1004) Program

    Edasalonexent (CAT-1004) Program Oral small molecule designed to inhibit NF-B for the treatment of Duchenne muscular dystrophy 5

  5. Slide 5: MoveDMD Open-Label Extension Results: Edasalonexent Substantially Slowed DMD Disease Progression

    MoveDMD® Open-Label Extension Results: Edasalonexent Substantially Slowed DMD Disease Progression Clinically meaningful slowing of disease progression on edasalonexent compared to off-treatment control period –North Star Ambulatory Assessment stabilized –All timed function tests stabilized (10-meter

  6. Slide 6: NF-kB Is a Fundamental Component of DMD Disease Progression

    NF-B Is a Fundamental Component of Duchenne Muscular Dystrophy Disease Progression DMD is a fatal disease caused by mutations in dystrophin resulting in a loss of dystrophin and progressive loss of muscle function NO DYSTROPHIN + MECHANICAL STRESS NF-B pathway is the key link between loss of dystrop

  7. Slide 7: DMD Is Characterized by a Predictable Cascade of Losses of Function and Mobility

    DMD Is Characterized by a Predictable Cascade of Discrete Losses of Function and Mobility Milestones Typical DMD Disease Progression Edasalonexent goal: of stair climb Loss of ambulation ath 0 5 10 15 20 25 30 DMD Patient Age, Years 8 Adapted from presentation by Dr. Craig McDonald, UC Davis NeuroNE

  8. Slide 8: MoveDMD Trial Designed to Enable Phase 3

    MoveDMD Trial Designed to Enable Phase 3 Phase 1 Phase 2 Open-Label Extension 12 weeks 7 days Average 39 weeks 100 mg/kg 31 Boys Ages 4 to 7 with DMD not on corticosteroids randomized Integrated 3-part trial design –Supported evaluation of efficacy, safety/tolerability, target engagement, and dose r

  9. Slide 9: MoveDMD Trial Incorporated Multiple Measures of Physical Function and Biomarkers

    MoveDMD Trial Incorporated Multiple Measures of Physical Function and Biomarkers Assessments of Physical Function Non-Effort Based Assessments 3 Timed Function Tests North Star Ambulatory Assessment 17 assessments, each scored 0-2. Maximum score: 34 Perform with difficulty 1 Unable to perform 0 Comp

  10. Slide 10: MoveDMD Population Reflects Broad Range of Mutations and Established Disease

    MoveDMD Population Reflects Broad Range of Mutations and Established Disease 26 Distinct Dystrophin Mutations in Boys Enrolled Marketed: Exon 51 Duplications In Development: Exons Point Mu 44, 45, 52, 53, 55 r Deletions Average Age in Trial At beginning of control period At beginning of active treat

  11. Slide 11: Boys in MoveDMD Trial Significantly Declined in Function During Off-Treatment Control Period

    Boys in MoveDMD Trial Significantly Declined in Function During Off-Treatment Control Period NSAA Time to Stand 40 0.5 0 0.4 30 Ill (/) ?2 0 Annual rate of decline: -4 points p-0.01 0.3 u (/) <i <i Annual rate of decline: -35% p<0.01 (/) co 20 . 0.2 "C (/) Ill z Ill Q. (/) 10 0.1 0 0.0 Start of Cont

  12. Slide 12: MoveDMD Results Open-Label Extension

    MoveDMD Results Open-Label Extension 13

  13. Slide 13: North Star Ambulatory Assessment Score Stabilized with Edasalonexent Treatment

    North Star Ambulatory Assessment Score Stabilized with Edasalonexent Treatment Pre-Specified Analysis North Star Ambulatory Assessment 25 20 15 10 5 -36 -24 -12 0 Weeks 12 24 36 North Star is a composite endpoint evaluating physical function across 17 tests Disease progression on edasalonexent impro

  14. Slide 14: Significant Reduction in North Star Score During Off-Treatment Control Period

    Significant Reduction in North Star the Off-Treatment Control Period Score During Individual changes during off-treatment control period Individual rates of change during off-treatment control period 40 0.2 0.0 30 -0.2 20 -0.4 10 -0.6 100 mg/kg (n=23) -0.8 0 -60 -48 -36 -24 -12 0 Weeks Prior to Trea

  15. Slide 15: North Star Ambulatory Assessment Score Stabilized: Individual Patient Results

    North Star Ambulatory Assessment Score Stabilized with Edasalonexent Treatment North Star Ambulatory Assessment Pre-Specified Analysis Individual Patient Results 25 10 20 5 15 0 10 -5 5 0 -10 -36 -24 -12 0 12 24 36 Weeks Disease progression on edasalonexent improved compared with rate of change duri

  16. Slide 16: Time to Stand Speed Stabilized with Edasalonexent Treatment

    Time to Stand Speed Stabilized with Edasalonexent Treatment Time to Stand Individual Patient Results Pre-Specified Analysis 0.05 0.3 0.00 0.2 5 -0.05 10 15 0.1 -0.10 0 -36 -24 -12 0 12 24 36 -0.15 Weeks Disease progression on edasalonexent improved compared with rate of change during off-treatment c

  17. Slide 17: 4-Stair Climb Speed Stabilized with Edasalonexent Treatment

    4-Stair Climb Speed Stabilized with Edasalonexent Treatment 4-Stair Climb Individual Patient Results Pre-Specified Analysis 0.2 0.4 0.1 0.3 0.0 5 0.2 -0.1 10 15 0.1 control period 0 -0.2 -36 -24 -12 0 12 24 36 Weeks Disease progression on edasalonexent improved compared with rate of change during of

  18. Slide 18: 10-Meter Walk/Run Speed Stabilized with Edasalonexent Treatment

    10-Meter Walk/Run Speed Stabilized with Edasalonexent Treatment 10-Meter Walk/Run Pre-Specified Analysis Individual Patient Results 0 . 1 0 0.20 5 0 . 0 5 0.18 0.16 0 . 0 0 0.14 control period - 0 . 0 5 0.12 10 - 0 . 1 0 -36 -24 -12 0 12 24 36 Weeks Disease progression on edasalonexent improved comp

  19. Slide 19: Edasalonexent Treatment Showed a Positive Dose Response

    Edasalonexent Treatment Showed a Positive Response Dose North Star Patient by Patient 10 5 0 -5 -10 MoveDMD trial evaluated 33 mg/kg BID (67 mg/kg/day) and 33 mg/kg TID (100 mg/kg/day) Data from preclinical studies highlight importance of time above exposure threshold achieved by more frequent dosin

  20. Slide 20: Edasalonexent Significantly Improved Rate of Change of MRI T2

    Edasalonexent Significantly Improved Rate of Change of MRI T2 Compared with Pre-Specified Control Period MRI T2 Rates of Change MRI T2 increases over time in DMD and is highly correlated with worsening timed function tests 0.15 0.10 Rate of change in boys on active treatment improved significantly c

  21. Slide 21: MRI T2 Rate of Change Stabilized with Edasalonexent Treatment

    MRI T2 Rate of Change Stabilized with Edasalonexent Treatment Individual Patient MRI T2 55 50 45 40 35 30 Control Week 0 Week 12 Week 24 Week 36 MRI T2 increases in DMD boys and was observed to increase during the off-treatment control period in the MoveDMD trial For boys in the 100 mg/kg edasalonex

  22. Slide 22: Muscle Enzymes Significantly Decreased from Baseline on Edasalonexent

    Muscle Enzymes Significantly Decreased from Baseline on Edasalonexent Consistent with positive impact on muscle health and supportive of an edasalonexent benefit Creatine Kinase Alanine Aminotransferase 5000 100 0 0 -5000 10000-15000-20000--100 * -200 12 24 36 12 24 36 Weeks on Edasalonexent 100 mg/

  23. Slide 23: Edasalonexent Significantly Reduced Plasma C-Reactive Protein Compared with Baseline

    Edasalonexent Significantly Reduced Plasma C-Reactive Protein Compared with Baseline CRP C-reactive protein (CRP) is a well-characterized blood test marker that provides a global assessment of inflammation 10 CRP is elevated in DMD –CRP approximately 3-fold higher in boys affected by DMD compared to

  24. Slide 24: Well Tolerated with No Safety Signals

    Well Tolerated with No Safety Signals No safety signals in MoveDMD trial to date 100 50 Well tolerated, with majority of adverse events being mild in nature, mostly gastrointestinal –Most common treatment-related adverse events were mild diarrhea –No serious treatment-related adverse events or dose

  25. Slide 25: Potential for Edasalonexent to Have Positive Effects on Cardiomyopathy in DMD

    Potential for Edasalonexent to Have Positive Effects on Cardiomyopathy in DMD Inhibiting NF-B reduces cardiac fibrosis in mdx mice and GRMD dog 9 mdx Mouse Model GRMD Dog Model Untreated CAT-1041 Untreated CAT-1041 6 3 Masson’s Trichrome Staining Masson’s Trichrome Staining 0 Untreated mdx mdx CAT-1

  26. Slide 26: Positive MoveDMD Data Support Planned Global Phase 3 Registration Trial

    Positive MoveDMD Data Support Planned Global Phase 3 Registration Trial for Edasalonexent Primary Endpoint Key Phase 3 trial components, including patient population and endpoints, previously evaluated in MoveDMD trial Enrollment of approximately 125 boys, 2:1 randomization, accounting for dropouts

  27. Slide 27: Edasalonexent Increases Dystrophin Expression in Combination with Exon-Skipping in mdx Mice

    Edasalonexent Increases Dystrophin Expression in Combination with Exon-Skipping in mdx Mice 10 Edasa Exon Skip Exon Skip + Edasa *p<0.05 5 Exon Skip Exon Skip + Edasa wild type/saline mdx/saline mdx/edasa mdx/M23D mdx/M23D/edasa Activated NF-B increases the expression of several microRNAs that suppr

  28. Slide 28: Edasalonexent Has Broad Potential as a Foundational Therapy for DMD

    Edasalonexent Has Broad Potential as a Foundational Therapy for DMD All DMD patients regardless of mutation type – Approximately 15,000 patients in US and 19,000 in EU Delays DMD disease progression – most important objective for a therapy for patients and parents Monotherapy and in combination with

  29. Slide 29: CAT-5571 Program

    CAT-5571 Program Oral small molecule designed to activate autophagy to restore host defense for the treatment of cystic fibrosis (CF) 30

  30. Slide 30: Autophagy: Maintains Host Defense Against Infection

    Autophagy: Maintains Host Defense Against Infection Foreign pathogens Autophagy Depressed in cystic fibrosis Critical component of immunity and host defense Important for clearance of pathogens Lysosome Elimination of pathogens 31

  31. Slide 31: CAT-5571 Restores Autophagy in CF Cells

    CAT-5571 Restores Autophagy in CF Cells CAT-5571 restores autophagy activation in mouse CF macrophages 0.8 * ** 0.6 0.4 0.2 Normal CF Vehicle CF CAT-5571 CAT-5571 has also been demonstrated to restore autophagy in primary bronchial epithelial cells from people with CF * ** p< 0.05 compared to Normal

  32. Slide 32: CAT-5571 Reduces Pulmonary Infection and Lung Inflammation in CF Mice

    CAT-5571 Reduces Pulmonary Infection and Lung Inflammation in CF Mice CAT-5571 significantly reduces pulmonary P. aeruginosa infection CAT-5571 significantly reduces pulmonary inflammation 1x1006 40 30 1x1005 20 1x1004 10 1x1003 0 Vehicle CAT-5571 Vehicle CAT-5571 CAT-5571 also significantly reduces

  33. Slide 33: CAT-5571: Breaking the Spiral of Cystic Fibrosis Progression

    CAT-5571: Breaking the Spiral of Cystic Fibrosis Progression Novel mechanism of action –Activates depressed autophagy, restoring host defense to clear pathogens Host-directed therapy –Potential to avoid typical bacterial resistance mechanisms Targets difficult to treat pathogens –Pseudomonas –Burkho

  34. Slide 34: Pipeline of Product Candidates in Rare Diseases

    Pipeline of Product Candidates in Rare Diseases e ase 3 in uscular dystrophy are disease • s ataxia • Con 35 Product Candidate (Pathway) Discovery Preclin Phase 1 Phase 2 Phase 3 Edasalonexent CAT-1004 (NF-B) Duchenne m • Phase 2 complet • Plan to start Ph H1 2018 Edasalonexent CAT-1004 (NF-B) Addit

  35. Slide 35: Pipeline of Product Candidates in Rare Diseases

    Pipeline of Product Candidates in Rare Diseases Product Candidate (Pathway) Discovery Preclin Phase 1 Phase2 Phase 3 Edasalonexent + Phase 2 complete CAT-1004 Duchenne muscular dystrophy + Plan to start Phase 3 in (NF-xB) Hi 2018, Edasalonexent CAT-1004 Additional rare disease (NF-KB) CAT-5571 + IND

Catabasis Pharmaceuticals — Investor Presentation (December 2017) on 6ix